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Abstract
Background: Obesity, an epidemic among West Virginia children, as well as insulin resistance (IR), is well-
established contributors to nonalcoholic steatohepatitis (NASH). Progression of NASH can lead to hepatic fibrosis
and cirrhosis, making early detection imperative. The standard for diagnosing NASH is histologically via liver biopsy,
which is highly invasive and generally contraindicated in children. By studying serum biomarkers associated with
NASH, we aim to identify high risk children who can benefit from a less invasive, alternative approach to the early
detection of NASH.
Methods: Seventy one children were prospectively recruited and divided into 3 groups: normal weight without IR
(control), obese without IR, and obese with IR. Serum samples were drawn for each patient and biomarker levels
were assessed via ELISA kits.
Results: Obese without IR and obese with IR patients had significantly elevated levels of lipid metabolism and
accumulation markers (FGF-21, NEFA, FATP5, ApoB), oxidative stress markers (dysfunctional HDL, 8-Isoprostane),
inflammatory markers(dysfunctional HDL, CK-18) and apoptosis markers (CK-18) compared to control patients
(p<0.02). Bilirubin (an antioxidant) was significantly decreased in the obese without IR and obese with IR patients
compared to control (p<0.02).
Conclusion: This study showed a correlation between obesity, IR, and biomarkers associated with NASH in
pediatrics patients from West Virginia, with obese with IR patients showing the strongest correlation. These findings
support the clinical application of these serum biomarkers as a less invasive method for early detection of NASH and
hepatic fibrosis.
Keywords: Biomarkers; Pediatric Non-alcoholic steatohepatitis
(NASH); Nonalcoholic fatty liver (NAFL)
Abbreviations
NASH: Nonalcoholic Steatohepatitis; NAFLD: Nonalcoholic Fatty
Liver Disease; IR: Insulin Resistance, FGF-21: Fibroblast Growth
Factor-21; NEFA: Non-Esterified Fatty Acid; FATP5: Fatty Acid
Transporter 5; FFA: Free Fatty Acid; Apo-B: Apolipoprotein B; oxHDL:
oxidized High Density Lipoprotein; CK-18: Cytokeratin-18; BMI:
Body Mass Index; ALT: Alanine Aminotransferase; HOMA2-IR:
Homeostasis Model Assessment-Insulin Resistance; TG: Triglycerides;
ROS: Reactive Oxygen Species; IL-6: Interleukin-6
Introduction
Obesity levels worldwide have reached epidemic proportions, with
an estimated 1.5 billion adults and 200 million school-age children
around the world either overweight or obese [1,2]. Paralleling the
recent increase in obesity prevalence are its comorbidities, including
type 2 diabetes mellitus (T2DM), insulin resistance, and nonalcoholic
fatty liver disease [3-5]. NAFLD is histologically further characterized
into nonalcoholic fatty liver, which is defined as lipid accumulation
present in greater than 5% of hepatocytes or affecting greater than 5%
of liver volume in the absence of significant alcohol consumption, with
no evidence of hepatocellular injury in the form of ballooning of the
hepatocytes [6-8].
NAFLD is the most common liver disorder in the world, estimated
to affect 20-40% of the population in developed nations, and up to 95%
of obese people and 70% of patients with T2DM [3,6,9,10]. Though
NAFL is generally asymptomatic, approximately 30% of NAFL cases
progress to nonalcoholic steatohepatitis, which is histologically
characterized by steatosis and inflammation with hepatocyte injury
(ballooning), with or without fibrosis [11,12], and approximately 20%
of NASH cases progress to liver cirrhosis [12]. NAFL and NASH are
now the leading causes of chronic liver disease worldwide and NASH is
expected to surpass alcohol and hepatitis as the leading cause of
cirrhosis [13]. Approximately 7-14% of patients referred for liver
transplantation in the United States are known to have NASH, or
cirrhosis due to NASH [14].
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Currently the gold standard for diagnosing NASH is via liver biopsy.
Given the extent and burden of NAFLD in the population, liver biopsy
is not logistically feasible in many parts of the country where there is
limited access to health care. Percutaneous liver biopsy is highly
invasive and subject to complications, including mortality, with a rate
of 1 in 10,000 [15]. It is also costly and subject to sampling variability,
thus, biopsy is unsuitable for longitudinal monitoring and not ideal for
diagnosis [16]. Ultrasound is used by some, in conjunction with labs
such as aminotransferases, to monitor progression. Ultrasound has a
high sensitivity (89%) and specificity (93%) for recognizing steatosis,
however its utility in detecting fibrosis has mixed results [17]. Because
of all of these limitations, there has been increasing interest in finding
noninvasive biomarkers to diagnose and monitor disease progression.
Based on a review of the literature, three clinical markers and eight
serum biomarkers were selected because they have shown an
association with NASH in adult and/or pediatric patients. However,
there is a paucity of studies within the pediatric population with regard
to serological markers. This study will establish a panel of these
biomarkers that will provide a minimally invasive means to detect
and/or monitor NASH in pediatric patients by targeting the different
mechanistic steps by which NASH develops: fat accumulation,
oxidative stress, inflammation, and apoptosis (Figure 1) [15].
Figure 1: Primary mechanisms involved in the development of
NAFLD. Reactive oxygen species (ROS).
The goal of this panel would be to promote early detection and
follow up of pediatric patients with a minimally invasive, reliable, cost
effective, and logistically feasible approach in areas where obesity and
its comorbidities are salient, and where health care services may be
limited, such as West Virginia.
Materials and Methods
Patients
Children, between the ages of 8-18 years old who attended the
gastroenterology clinic were prospectively recruited to the study.
Exclusion criteria included children with various systemic diseases that
affect the immune system such as celiac disease, inflammatory bowel
disease, or children with endocrine problems including
hypothyroidism, hypocalcemia, children with primary metabolic
diseases (dyslipidemia, etc.), or drug induced obesity (steroids).
Children were divided into 3 groups: normal weight children without
IR (control), obese children without IR, and obese children with IR.
The study was approved by the Joan C Edwards School of Medicine,
Marshall University IRB committee.
Blood samples and biomarker quantification
After a consent form was signed by one of the parents and the child
when appropriate and after overnight fasting, venous blood was drawn
from the participants and serum was stored at -80°C until analyzed.
The following serum concentrations were measured by enzyme linked
immunosorbent assay kits (ELISA) according to the manufacturer’s
protocols: CK-18, FATP5, OxHDL/HDL and NEFA (Mybiosource, San
Diego, CA); ApoB and FGF-21 (Abcam, Cambridge, MA); bilirubin
(Sigma Aldrich, St. Louis, MO); 8-isoprostane(Cayman Chemical, Ann
Arbor, MI). Aminotransferase (ALT) was measured by the hospital
according to the International Federation of Clinical Chemistry and
Laboratory Medicine standard enzymology methods. Insulin
resistance was determined by the HOMA-2 equation and values >2.0
were considered positive for IR [18]. Obesity was defined by the CDC
BMI growth charts for both genders (>95% tile).
Statistics
Data were analyzed using Graphpad Prism 4.0. Equal variance was
assured by Bartlett’s test for each biomarker within each of the three
patient categories. ANOVA was conducted to identify statistically
significant differences in the mean serum levels for the different
biomarkers. The Tukey post-hoc test was used to indicate which
patient groups showed statistically significant differences for the
biomarker level measured.
Results
Seventy one patients were recruited into the study and divided into
three groups: normal weight without insulin resistance (n=28), obese
without insulin resistance (n=16), and obese with insulin resistance
(n=27). All participants were Caucasians, and male/female ratio was
1.3:1, 1.27:1, and 2:1, for the control, obese without IR, and obese with
IR, respectively. There was no difference between the groups in the
mean age or gender ratio. Overall, children with obesity and IR showed
significant differences in almost all indices compared to normal weight
children and obese children without IR (Tables 1 and 2).
Clinical markers: BMI, HOMA-IR, ALT
BMI was significantly elevated in obese without IR and obese with
IR patients, while HOMA-IR was only elevated in patients who were
obese with IR, compared to the control (p<0.02) (Table 1). Alanine
aminotransferase (ALT), a marker of fibrosis, was also found to be
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significantly higher in obese with IR patients compared to obese
without IR and to control (p<0.02). These three variables are easy to
obtain clinical markers that can aid in the diagnosis of NASH.
Serum biomarkers to study lipid metabolism and
accumulation: FGF-21, NEFA, FATP5, ApoB
Markers related to fat metabolism and accumulation (FGF-21,
NEFA, FATP5, ApoB) were significantly elevated in the obese and
obese+IR groups compared to the control group (p<0.02) (Table 2).
Additionally, ApoB and NEFA were significantly elevated in the obese
+IR group compared to the obese group (p<0.02). FATP5 and FGF-21
however showed no significant difference between the obese+IR and
obese group.
Group Control Obese Obese + IR
# Pts 28 16 27
BMI 20.87 (± 0.5) 29.63 (± 1.3)* 31.81 (± 1.1)*
HOMA2-IR 1.14 (± 0.7) 1.29 (± 0.1) 3.44 (± 0.2)*#
ALT 16.20 (± 0.6) 20.88 (± 4.2) 46.62 (± 16.5)*
Values represent means ± SEM. *p<0.02 vs. control, #p<0.02 vs. obese.
Body mass index (BMI), HOMA2-IR and serum concentrations of alanine aminotransferase (ALT) in control, obese without IR, and obese with IR patients.
Table 1: Clinical markers.
Group Mechanistic Step Control Obese Obese + IR
# Pts 28 16 27
FGF-21 (ng/mL) Fat Metabolism 0.608 (± 0.02) 0.964 (± 0.03)* 0.971 (± 0.05)*
NEFA (µmol/L) Fat Accumulation 0.47 (± 0.07) 0.88 (± 0.03)* 1.28 (± 0.04)*#
FATP5 (ng/mL) Fat Inflow 8.00 (± 0.32) 9.46 (± 0.32)* 9.59 (± 0.29)*
ApoB (µg/mL) Fat Outflow 1419.79 (± 37.07) 1713.12 (± 31.94)* 1914.59 (± 48.87)* #
Bilirubin (mg/dL) Antioxidant 0.739 (± 0.04) 0.459 (± 0.03)* 0.430 (± 0.02)*
8-Isoprostane (pg/mL) Oxidative Stress 7.34 (± 0.37) 10.54 (± 0.39)* 11.02 (± 0.44)*
Dysfunctional HDL Oxidative Stress
Inflammation
2382.75 (± 51.48) 3059.90 (± 114.62)* 3414.76 (± 146.04)*#
CK-18 (ng/mL) Inflammation
Apoptosis
57.10 (± 1.32) 68.22 (± 1.59)* 90.48 (± 2.14)*#
Values represent means ± SEM. *p<0.02 vs. control, #p<0.02 vs. obese. Concentrations of biomarkers for fat accumulation, oxidative stress, inflammation, and
apoptosis assessed via ELISA in control, obese without IR, and obese with IR patients.
Table 2: Serum biomarkers.
Serum biomarkers to study oxidative stress: Dysfunctional
HDL, 8-Isoprostane, Bilirubin
Oxidative stress markers were also significantly different between
the groups. Obese and obese+IR showed a significantly higher
dysfunctional HDL (calculated by oxHDL to HDL ratio) compared to
the control group (p<0.02). Dysfunctional HDL was also significantly
higher in the obese+IR compared to the obese group (p<0.02) (Table
2). 8-Isoprostane, also a marker of oxidative stress, was significantly
elevated in the obese and obese+IR groups compared to control
(p<0.02). Conversely, bilirubin, which is an antioxidant compound,
was significantly decreased in patients who were obese without IR and
obese with IR compared to the control (p<0.02).
Serum biomarkers to study inflammation and apoptosis:
CK-18
Fragmented CK-18, a liver-specific cytoskeletal protein, is a marker
for inflammation and hepatocyte apoptosis. In the obese and obese
with IR patients, levels of CK-18 were significantly increased when
compared to the control (p<0.02) (Table 2). Obese with IR patients
showed significantly higher levels of CK-18 compared to obese without
IR patients (p<0.02).
Discussion
The goal of this study was to investigate serum biomarkers for the
early detection of NASH and hepatic fibrosis in children. Currently the
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most reliable method of diagnosing fatty liver is histologically via
biopsy. This method of diagnosis is invasive and because NASH lesions
may be distributed irregularly throughout the liver, it can result in a
false negative if unaffected tissue is biopsied or variability between
lesioned samples can complicate the diagnosis [8,10,19]. Additionally
biopsy is generally contraindicated in children except in rare cases
where fatty liver occurs secondary to a primary liver disease [1]. For
these reasons, a reliable serum biomarker panel can provide an
alternative to biopsy, particularly for children in at-risk demographics
for whom biopsy is not specifically indicated. In this cross-sectional
study, three groups of pediatrics patients, separated according to BMI
and HOMA2-IR scores, were assessed for biomarkers associated with
NASH, including those related to lipid metabolism and accumulation,
hepatic oxidative stress and inflammation and apoptosis.
Lipid metabolism and accumulation
Biomarkers for lipid and carbohydrate metabolism have been
associated with fatty liver. FGF-21 regulates lipid and carbohydrate
metabolism by decreasing lipolysis in adipocytes, which decreases
serum NEFA, and increasing glucose uptake in adipocytes via
upregulation of GLUT-1 [20]. FGF-21 also decreases hepatic
lipogenesis, upregulates enzymes for hepatic fatty acid oxidation, and
has been shown to reverse hepatic steatosis in mice and non-human
primates [21,22]. Although FGF-21 has beneficial effects on lipid
metabolism and is protective against hepatic steatosis, fatty liver has
been associated with elevated FGF-21, possibly either as compensation
for increased hepatic steatosis, or because fatty liver is associated with
FGF-21 resistance [22]. In our study, increased serum FGF-21 was
associated with increased BMI. Previous studies have demonstrated
that FGF-21 levels are increased in association with obesity and
hepatic steatosis either because of unfavorable lipid and glucose
metabolism associated with these conditions, or because these
conditions are associated with FGF-21-resistance [22].
There are several species of lipids present in the liver, but the
primary form of fat is triglycerides. Based on both human and animal
studies, expansion of the intrahepatic pool of FFAs is the reason for
triglyceride accumulation in NAFLD (Figure 2) [23]. In patients with
NAFLD, the pathways which lead to FFA efflux are usually functioning
at a higher level, indicating that the critical step leading to fat
accumulation is related to excessive inflow of FFA. FFA influx depends
on several factors including the amount of FFA released by adipose
tissue (due to insulin resistance and excessive lipolysis), dietary fat via
chylomicron metabolism, and de novo synthesis (Figure 2). Studies
have shown that more than half (up to 75%) of the FFA pool is derived
from excess adipose tissue lipolysis [24]. Free fatty acids may be
disposed of from the liver via fatty acid oxidation or through the
assembly and export of triglycerides with VLDL.
Hepatic lipid flux involves inflow via NEFA and FFA through fatty
acid transport protein 5 (FATP5) and outflow via apolipoprotein B
(ApoB)-containing lipoproteins (LDL, IDL, and VLDL). Obesity and
IR are associated with increased serum levels of NEFA [25-27], which
have been associated with development and progression of fatty liver
[28-30]. NEFA contributes directly to hepatic fat deposits [30,31],
hepatic IR [25] and oxidative lipotoxic ER stress [31], which can drive
NAFLD progression. Our results showed an association between BMI
and IR and increased NEFA levels, which is consistent with the
literature.
FATP5, a liver specific integral transmembrane protein, enhances
the uptake of long chain and very long chain fatty acids. Increased
FATP5 activity is associated with fatty liver [32], while decreased
FATP5 activity has been shown to reverse hepatic steatosis [33]. Our
results demonstrated that increases in FATP5 levels were associated
with increases in BMI and IR.
Figure 2: Schematic representation demonstrating lipid transport
and free fatty acid (FFA) flux in insulin resistant states. Insulin
resistance results in increased FFA in plasma, which leads to
increased hepatocellular triglyceride (TG) concentrations.
Chylomicrons, containing apoB-48, also contributes to hepatic
steatosis. FFA enter the liver via fatty acid transporters (FATP),
mainly FATP5. Elevated hepatic triglycerides levels leads to
increased hepatocyte secretion of very low density lipoprotein
(VLDL), which contains apoB-100. Insulin resistance also leads to
defective hepatic mitochondrial function, resulting in decreased
fatty acid oxidation in the liver.
ApoB, a biomarker of lipid outflow, is stimulated in response to
intrahepatic triglyceride availability. Elevated serum ApoB is
associated with fatty liver and has been investigated as a possible
biomarker [30,34]. Though it seems that increased ApoB levels would
result in net lipid clearance from the liver, it is believed that the
elevated ApoB associated with fatty liver arises secondary to increased
hepatic TG, as VLDL synthesis is stimulated by TG, but is inadequate
in clearing the elevated hepatic lipids [30,32]. Our results indicated
that compared to control, obese and IR patients were more likely to
have clinical indications of net hepatic lipid influx, which is associated
with hepatic steatosis: children with both obesity and IR had profiles
associated with the greatest degree of net hepatic lipid influx.
Oxidative stress
While fat accumulation is the common denominator of all forms of
NAFL, an important distinction to make is that fatty infiltration alone
does not lead to NASH and cirrhosis. Excess lipid accumulation results
in toxic effects on hepatocytes: oxidative stress triggers inflammation
and wound healing that eventually causes fibrosis [23]. Lipid
accumulation and lipotoxicity can contribute to inflammatory changes
that result in NASH, whereas antioxidant activity within the liver is
believed to protect hepatocytes from oxidative stress [1,8,10,19,35].
Thus, oxidative stress plays a central role in hepatocyte injury and
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disease progression from simple steatosis to NASH. Several oxidation
pathways may play a role in the overproduction of lipid peroxidation
products in NASH patients which can provide quantifiable biomarkers.
Furthermore, hepatic antioxidant activity is another way to detect
NASH as it negatively correlates with NASH severity.
Bilirubin, an end product of heme metabolism, positively correlates
with antioxidant activity, and its antioxidant properties exert a
cytoprotective effect on hepatocytes. Previous studies have associated
bilirubin with increased antioxidant activity via prevention of aberrant
lipid oxidation and decreased oxidative lipotoxicity [36]. On the other
hand, increasing ROS and oxidative stress leads to lipid peroxidation
which in turn causes dysfunctional HDL [37]. oxHDL is a product of
aberrant lipid oxidation and is a dysfunctional form of HDL that
negatively correlates with antioxidant activity. Certain conditions,
including high fat diets and diabetes mellitus, are associated with these
modifications of HDL such that it paradoxically enhances LDL
oxidation and/or vascular inflammation [38]. “Dysfunctional HDL” is
calculated from the ratio of oxidized HDL to HDL [39]. Similarly,
isoprostanes are also a marker of oxidative stress which can be
measured in plasma, urine, and other biological fluids which is why
they are appealing to use as biomarkers. They are prostaglandin-like
compounds produced via the cyclooxygenase independent, free radial-
catalyzed oxidation of arachidonic acid. 8-Isoprostane is a
prostaglandin-F2-like compound belonging to the F2 isoprostane class
[40]. 8-Isoprostane has been shown to be increased in NAFLD and
NASH [41-43].
Based on a review of the literature, it appears that NASH is
associated with decreased bilirubin, increased dysfunctional HDL, and
increased 8-isoprostane levels, indicating increased hepatocyte
susceptibility to oxidative stress [42,44]. Within this study, bilirubin
levels decreased, dysfunctional HDL levels increased, and 8-
isoprostane levels increased in association with increases in BMI and
IR, demonstrating increasing oxidative stress with increasing BMI and
IR. Our results indicate that obese and IR patients are more likely to
exhibit markers of oxidative lipotoxicity, a mechanism that can drive
the onset and progression of NASH.
Inflammation
Chronic systemic inflammation plays a critical role in the
development and progression of NAFLD from simple steatosis,
however the exact mechanisms by which inflammation leads to NASH
is still unclear [44]. It is believed that insulin resistance and a chronic
low grade inflammation are through to lead to the development of
NAFLD in genetically predisposed individuals. The chronic
inflammation in NAFLD begins within the adipose tissue and worsens
with insulin resistance [45]. Several inflammatory markers, which also
happen to be markers of oxidative stress and apoptosis, have been
proposed as markers for NASH. Given the complicated nature of
NASH progression, starting with lipid metabolism and accumulation,
and leading to oxidative stress, inflammation and apoptosis, many
markers are involved in multiple steps of the process and cannot be
delineated so neatly. Such markers of inflammation include elevated
dysfunctional HDL, increased IL-6 [46], increased leptin [47], and
decreased adiponectin [47] which have demonstrated associations with
NASH in the literature and our prior studies.
HDL may be viewed as a vehicle for lipids or proteins that can be
either anti-inflammatory or proinflammatory, depending on its cargo,
but dysfunctional HDL is proinflammatory. Dysfunctional HDL’s
proinflammatory status can improve with resolution of systemic
inflammation or lifestyle and therapeutic interventions [39]. CK-18 is
also recognized as a marker of liver inflammation and has been added
to the panel as it is both a marker of inflammation and apoptosis
[15,48]. In our studies, both dysfunctional HDL and CK-18 levels were
significantly elevated in the obese and obese with IR patients
compared to control and in the obese with IR compared to the obese
patients.
Apoptosis
Apoptosis, or programmed cell death, has emerged as an important
mechanism in disease progression of NASH. Apoptosis is a highly
organized process that can occur via the extrinsic or intrinsic pathway.
Both pathways can lead to the activation of caspases, which cleave
intracellular substrates, including cytokeratin-18 (CK-18), which is the
major intermediate filament protein in hepatocytes [49]. CK-18 is a
liver-specific cytoskeletal protein that is cleaved by caspases during
hepatocyte apoptosis, releasing fragments that are detectable in serum
samples [9,50,51]. Elevated serum CK-18 fragment levels have
previously been shown to positively correlate with steatosis severity,
lobular inflammation, and fibrosis stage, with markedly increased
levels in patients with NASH compared to those with simple steatosis
[11,52-54]. Previous studies have also shown serum CK-18 fragment
levels correlated positively with the severity of hepatic inflammation
and hepatocyte apoptosis associated with NASH [11,50-54]. CK-18
fragments have been validated as a marker of NASH in many studies
and it has even been recognized as the most promising noninvasive test
for diagnosing and managing NASH in recent NAFLD guidelines [15].
According to our results, serum CK-18 fragment levels were
significantly increased in the obese and obese with IR patients
compared to control and significantly increased in the obese with IR
compared to the obese. The clinical index of suspicion for NASH
should be high in the obese with IR group as they showed the greatest
increase.
In conclusion, because obesity and IR are increasing in prevalence,
and because they are risk factors for the development of NASH and
hepatic fibrosis, early detection and therapy is becoming increasingly
important. Our study identified a panel of serum biomarkers in
children that is associated with obesity and IR. Given the strong
relationship between obesity, IR, and NASH, this panel could function
as a NASH screening tool for at-risk children. This is particularly
important because liver biopsy is generally contraindicated in children
and is too invasive for repeated monitoring of disease progression.
Therefore, a reliable serum panel that is capable of identifying early
NASH and fibrotic activity can provide a less invasive alternative and
encourage early detection in at-risk children.
Implications
Our study investigated the clinical efficacy of serum biomarkers in
early detection of NASH and hepatic fibrosis in at-risk Appalachian
children. Childhood obesity, IR, and their comorbidities are reaching
epidemic proportions worldwide, with rural Appalachia suffering some
of the highest rates. The poverty level within the region also
underscores the importance of early detection and treatment while
these conditions can be managed with minimal and relatively
inexpensive intervention. The results of this study can benefit
medically underserved populations by providing a reliable and less-
invasive clinical approach that can serve to encourage early detection
and monitoring of NASH and hepatic fibrosis in these at-risk patients.
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